Oral delivery of peptides and proteins using lipid-based drug delivery systems

Expert Opinion on Drug Delivery

Volumn 9, Issue 10, 2012, Pages 1289-1304

  Li, Ping ^a   Nielsen, Hanne Morck ^a   Müllertz, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

(micro)emulsions; Drug delivery systems; Liposomes; Mucoadhesion; Particles; Permeability; SLN; Stability

Indexed keywords

ADAMANTANE DERIVATIVE; ADAMANTYLTRIPEPTIDE; ALBUMIN; BOVINE INSULIN; BOVINE SERUM ALBUMIN; CLATHRIN; EARTHWORM FIBRINOLYTIC ENZYME; EPIDERMAL GROWTH FACTOR; FATTY ACID; GONADORELIN; HUMAN GROWTH HORMONE; HUMAN INSULIN; INSULIN; LEUPRORELIN; LIPID; LIPID EMULSION; LIPOSOME; LYSOZYME; OLIVE OIL; PEPTIDE; PHOSPHOLIPID; PIG INSULIN; PLASMIN; PROTEIN; SALCATONIN; SOLID LIPID NANOPARTICLE; THYMOPENTIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIOCOMPATIBILITY; BIODEGRADABILITY; BIOTECHNOLOGY; CELL SIZE; CHEMICAL COMPOSITION; COLLOID; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; ENDOCYTOSIS; ENZYME DEGRADATION; GASTROINTESTINAL TRACT; HUMAN; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIPID ANALYSIS; LIPID BILAYER; LIPID METABOLISM; LIPOPHILICITY; LIPOSOMAL DELIVERY; MEMBRANE PERMEABILITY; MICROEMULSION; MOUTH MUCOSA; PARTICLE SIZE; REVIEW; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; INTESTINAL ABSORPTION; LIPIDS; LIPOSOMES; PEPTIDES; PERMEABILITY; PROTEINS;

EID: 84866875931     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.717068     Document Type: Review

References (104)

1. Kumar TRS, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 2006;7:261-76
2. FDA Product Label at FDA Drugs@FDA. 2006
3. Shen WC. Oral peptide and protein delivery: unfulfilled promises? Drug Discov Today 2003;8:607-8
4. Kyeongsoon Park ICKKP. Oral protein delivery: current status and future prospect. Reactive Funct Polymers 2011;71:280-7
5. Wang W. Oral protein drug delivery. J Drug Target 1996;4:195-232
6. Langguth P, Bohner V, Heizmann J, et al. The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release 1997;46:39-57
7. Pauletti GM, Gangwar S, Knipp GT, et al. Structural requirements for intestinal absorption of peptide drugs. J Control Release 1996;41:3-17
8. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliver Rev 2001;52:117-26
9. des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006;116:1-27
10. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci 2000;89:429-42
11. Pauletti GM, Gangwar S, Siahaan TJ, et al. Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 1997;27:235-56
12. Liu H, Tang R, Pan WS, et al. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J Pharm Pharmacol 2003;55:1523-9
13. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliver Rev 2001;47:39-54
14. Legrand P, Barratt G, Mosqueira V, et al. Polymeric nanocapsules as drug delivery systems-A review. Stp Pharma Sci 1999;9:411-18
15. Delie F, Blanco-Prieto MJ. Polymeric particulates to improve oral bioavailability of peptide drugs. Mol 2005;10:65-80
16. Breunig M, Bauer S, Goefferich A. Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur J Pharm Biopharm 2008;68:112-28
17. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009;61:158-71
18. Couvreur P, BlancoPrieto MJ, Puisieux F, et al. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. Adv Drug Deliver Rev 1997;28:85-96
19. Damge C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin on Drug Deliv 2008;5:45-68
20. Jaymin CS, Yogesh S, Dakshina MC. Cubic phase gels as drug delivery systems. Adv Drug Deliv Rev 2001;47:229-50
21. Rizwan SB, Boyd BJ, Rades T, et al. Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins. Expert Opin on Drug Deliv 2010;7:1133-44
22. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomed 2007;2:743-9
23. Cheng JJ, Teply BA, Jeong SY, et al. Magnetically responsive polymeric microparticles for oral delivery of protein drugs. Pharmaceut Res 2006;23:557-64
24. Sinha VR, Singh A, Kumar RV, et al. Oral colon-specific drug delivery of protein and peptide drugs. Crit Rev Ther Drug Carrier Syst 2007;24:63-92
25. Sadeghi AMM, Dorkoosh FA, Avadi MR, et al. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur J Pharm Biopharm 2008;70:270-8
26. Knipp GT, Ho NFH, Barsuhn CL, Borchardt RT. Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci 1997;86:1105-10
27. Langkjaer L, Brange J, Grodsky GM, Guy RH. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J Control Release 1998;51:47-56
28. de Wit JN. Nutritional and functional characteristics of whey proteins in food products. J Dairy Sci 1998;81:597-608
29. Conradi RA, Hilgers AR, Ho NFH, Burton PS. The influence of peptide structure on transport across caco-2 cells. Pharmaceut Res 1991;8:1453-60
30. Foged C, Nielsen HM. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Del 2008; 5(1):105-17.
31. Mullertz A, Ogbonna A, Ren S, Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010;62:1622-36
32. Borgstrom B. Bile salts-their physiological functions in the gastrointestinal tract. Acta Med Scand 1974;196:1-10 . A good review of lipid-and surfactant-based DDS for poorly water-soluble drugs.
33. Fatouros DG, Deen GR, Arleth L, et al. Structural development of self nanoemulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle x-ray scattering. Pharmaceut Res 2007; 24:1844-53
34. Chen HM, Langer R. Oral particulate delivery: status and future trends. Adv Drug Deliver Rev 1998;34:339-50
35. Donald MS. A classification of biologic lipids based upon their interaction in aqueous systems. J Am Oil Chem Soc 1968;45:108-19
36. Ericsson B, Eriksson PO, Lofroth JE. Cubic phases as delivery systems for peptide drugs. In: Dunn RL, Ottenbrite RM, editors. Polymeric drug and drug delivery systems. Volumne 469 In: ACS Symposium Series 1991. 251-65
37. Shah MH, Paradkar A. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme. Int J Pharmaceut 2005;294:161-71
38. Morel S, Ugazio E, Cavalli R, Gasco MR. Thymopentin in solid lipid nanoparticles. Int J Pharmaceut 1996;132:259-61
39. Liu J, Gong T, Wang CG, et al. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharmaceut 2007;340:153-62
40. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 2005;25:133-43
41. Domb AJ. Lipospheres for controlled delivery of substances. WO9107171; 1996
42. Lee JH, Il Ahn S, Park JH, et al. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. J Tisuue Eng Regen Med 2008;5:215-28
43. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60
44. Zhang N, Ping QN, Huang GH, Xu WF. Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int J Pharmaceut 2005;294:247-59
45. Carafa M, Marianecci C, Annibaldi V, et al. Novel O- palmitoylscleroglucancoated liposomes as drug carriers: development, characterization and interaction with leuprolide. Int J Pharm 2006;325:155-62
46. Takeuchi H, Matsui Y, Sugihara H, et al. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int J Pharmaceut 2005;303:160-70
47. Thongborisute J, Tsuruta A, Kawabata Y, Takeuchi H. The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin. J Drug Target 2006;14:147-54
48. Trenktrog T, Muller BW. Preparation and characterization of a peptide-containing W/O emulsion. Int J Pharmaceut 1995;123:199-207
49. Dogru ST, Calis S, Oner F. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro in vivo evaluation. J Clin Pharm Ther 2000;25:435-43
50. Sharma G, Wilson K, van der Walle CF, et al. Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur J Pharm Biopharm 2010;76:159-69
51. Cheng MB, Wang JC, Li YH, et al. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. J Control Release 2008;129:41-8
52. Dogru ST, Calis S, Oner F. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro in vivo evaluation. J Clin Pharm Ther 2000;25:435-43
53. Ma EL, Ma H, Liu Z, et al. In vitro and in vivo evaluation of a novel oral insulin formulation. Acta Pharmacol Sin 2006;27:1382-8
54. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption-physical and biopharmaceutical aspects. Pharmaceut Res 1995;12:1561-72
55. Toorisaka E, Ono H, Arimori K, et al. Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oilin-water (S/O/W) emulsion. Int J Pharm 2003;252:271-4
56. Mesiha M, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty-acid sodium glycocholate emulsions. Int J Pharm 1994;111:213-16
57. New RRC, Kirby CJ. Solubilisation of hydrophilic drugs in oily formulations. Adv Drug Deliver Rev 1997;25:59-69
58. Li CL, Deng YJ. Oil-based formulations for oral delivery of insulin. J Pharm Pharmacol 2004;56:1101-7
59. Wang T, Wang N, Hao AJ, et al. Lyophilization of water-in-oil emulsions to prepare phospholipid-based anhydrous reverse micelles for oral peptide delivery. Eur J Pharm Sci 2010;39:373-9
60. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 2000;11:S93-8
61. Foger FA. Pharmaceutical compositions for oral administration of insulin peptides. WO2011086093; 2011
62. Rao SPVR, Shao J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs I. Formulation development. Int J Pharmaceut 2008;362:2-9
63. Bernkop-Schnurch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release 1998;52:1-16
64. Oliyai R, Stella VJ. Prodrugs of peptides and proteins for improved formulation and delivery. Annu Rev Pharmacol Toxicol 1993;33:521-44
65. Peppas NA. Devices based on intelligent biopolymers for oral protein delivery. Int J Pharmaceut 2004;277:11-17
66. Salmaso S, Bersani S, Elvassore N, et al. Biopharmaceutical characterisation of insulin and recombinant human growth hormone loaded lipid submicron particles produced by supercritical gas micro-atomisation. Int J Pharmaceut 2009;379:51-8
67. Zhang N, Ping QN, Huang GH, et al. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharmaceut 2006;327: 153-9
68. Watnasirichaikul S, Rades T, Tucker IG, Davies NM. In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J Pharm Pharmacol 2002;54:473-80
69. Takeuchi H, Sasaki H, Niwa T, et al. Design of redispersible dry emulsion as an advanced dosage form of oily drug (vitamin-e nicotinate) by spray-drying technique. Drug Dev Ind Pharm 1992;18:919-37
70. Linares E, Larre C, Popineau Y. Freeze-or spray-dried gluten hydrolysates. Biochemical and emulsifying properties as a function of drying process. J Food Eng 2001;48:127-35
71. Toorisaka E, Hashida M, Kamiya N, et al. An enteric-coated dry emulsion formulation for oral insulin delivery. J Control Release 2005;107:91-6
72. Katayama K, Kato Y, Onishi H, et al. Double liposomes: hypoglycemic effects of liposomal insulin on normal rats. Drug Dev Ind Pharm 2003;29:725-31
73. Li H, An JH, Park JS, Han K. Multivesicular liposomes for oral delivery of recombinant human epidermal growth factor. Arch Pharm Res 2005;28:988-94
74. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosornes for delivery of insulin. Int J Pharmaceut 2007;328:130-41
75. Li ZR, Chen J, Sun WQ, Xu YH. Investigation of archaeosomes as carriers for oral delivery of peptides. Biochem Bioph Res Co 2010;394:412-17
76. Nellans HN. Mechanisms of peptide and protein-absorption. Paracellular intestinal transport-modulation of absorption. Adv Drug Deliver Rev 1991;7:339-64
77. Malkov D, Wang HZ, Dinh S, Gomez-Orellana I. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate. Pharmaceut Res 2002;19:1180-4
78. Aungst BJ. Absorption enhancers: applications and advances. Aaps Journal 2011;14:10-18
79. du Plessis LH, Lubbe J, Strauss T, Kotze AF. Enhancement of nasal and intestinal calcitonin delivery by the novel pheroid (TM) fatty acid based delivery system, and by N-trimethyl chitosan chloride. Int J Pharmaceut 2010;385:181-6
80. Maher S, Leonard TW, Jacobsen J, Brayden DJ. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv Drug Deliver Rev 2009;61:1427-49
81. Soderholm JD, Oman H, Blomquist L, et al. Reversible increase in tight junction permeability to macromolecules in rat ileal mucosa in vitro by sodium caprate, a constituent of milk fat. Digest Dis Sci 1998;43:1547-52
82. Leonard TW, Lynch J, McKenna MJ, Brayden DJ. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin Drug Deliv 2006;3:685-92
83. Takeuchi H, Sugihara H. Absorption of calcitonin in oral and pulmonary administration with polymer-coated liposomes. Yakugaku Zasshi J Pharma Soc Jpn 2010;130:1135-42
84. Baluom M, Friedman DI, Rubinstein A. Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. Int J Pharm 1997;154:235-43
85. Akiyama Y, Nagahara N, Kashihara T, et al. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm Res 1995;12:397-405
86. Roy SK, Prabhakar B. Bioadhesive polymeric platforms for transmucosal drug delivery systems-a review. Trop J Pharm Res 2010;9:91-104
87. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release 2008;125:236-45
88. Sarmento B, Mazzaglia D, Cristina BM. Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr Polym 2011;84:919-25
89. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77
90. Tan ML, Choong PFM, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2010;31:184-93
91. Cao J, Sun J, Wang X, et al. N-trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev Ind Pharm 2009. 35(11):1339-47
92. Spernath A, Aserin A. Microemulsions as carriers for drugs and nutraceuticals. Adv Colloid Interface Sci 2006;128: 47-64
93. Prego C, Garcia M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release 2005;101:151-62
94. Almeida AJ, Runge S, Muller RH. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 1997; 149:255-65
95. Cavalli R, Bocca C, Miglietta A, et al. Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. Stp Pharma Sci 1999;9:183-9
96. Garcia-Fuentes M, Torres D, Alonso MJ. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloid Surf B 2003;27:159-68
97. Hu FQ, Hong Y, Yuan H. Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm 2004;273:29-35
98. Morel S, Gasco MR, Cavalli R. Incorporation in Lipospheres of [D-Trp-6]Lhrh (Vol 105, Pg R1, 1994). Int J Pharm 1995;119:126
99. Trotta M, Cavalli R, Carlotti ME, et al. Solid lipid micro-particles carrying insulin formed by solvent-in-water emulsion-diffusion technique. Int J Pharm 2005;288:281-8
100. Dos Santos IR, Richard J, Pech B, et al. Microencapsulation of protein particles within lipids using a novel supercritical fluid process. Int J Pharm 2002; 242:69-78
101. Iwanaga K, Ono S, Narioka K, et al. Application of surface coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J Pharm Sci 1999; 88:248-52
102. Frkanec R, Noethig-Laslo V, Vranesic B, et al. A spin labelling study of immunomodulating peptidoglycan monomer and adamantyltripeptides entrapped into liposomes. Biochim Biophys Acta Biomembr 2003;1611:187-96
103. Takeuchi H, Matsui Y, Sugihara H, et al. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int J Pharm 2005;303:160-70
104. Thongborisute J, Tsuruta A, Kawabata Y, Takeuchi H. The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin. J Drug Target 2006; 14:147-54